All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
ALL HubAML HubLymphoma HubMDS HubMPN HubMultiple Myeloma

How do we stratify risk in patients with GvHD?

Apr 11, 2022
Learning objective: After listening to this podcast, learners will be able to cite a new clinical development in GvHD.

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub was pleased to speak to Daniel Weisdorf, University of Minnesota, Minneapolis, US. We asked, How do we stratify risk in patients with GvHD? 

How do we stratify risk in patients with GvHD?

Weisdorf begins by discussing the Minnesota Risk Score (M. MacMillan, et al.), which uses the stage of skin, liver, and gut involvement in GvHD to predict the response to therapy. Weisdorf then talks about the potential of incorporating biomarkers into the Minnesota Risk Score in the future.